Wij zijn onze website aan het vernieuwen.

Ontdekt u nog een pagina die niet klopt of hebt u een goede suggestie, laat het ons dan weten via webmedia@umcutrecht.nl.

Deze website maakt gebruik van cookies

Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Lees meer over het cookiebeleid.

prof. dr. M.C. (Monique) Minnema Full Professor

  • Department of Medical Oncology

M.C. Minnema

Contact

Research Programs

Biography

Prof Dr Monique Minnema was trained as internist and hematologist at Academic Medical Center, Amsterdam and the University Medical Center, Utrecht. She started working as a hematologist in 2005 at the department of hematology, UMC Utrecht and specialized in the diagnosis and treatment of B cell malignancies, especially plasma cell dyscrasis  like Multiple Myeloma and AL amyloidosis, and Waldenstrom Macroglobulinemia.
She is the medical head of the hematology research team which supervises more
than 20 clinical studies. Her main focus of clinical research is the
development of novel therapies (both cellular and drug) developments for plasma
cell dyscrasias and she was appointed full professor of hematology in 2019.

Prof Dr Minnema is an active member of the HOVON working parties for Multiple
Myeloma, Lymphoma and the vice president of the Lunenburg Lymphoma consortium (LLPC) for phase I/II studies. Examples of her work are the HOVON 104 trial for
patients with AL amyloidosis first line treatment and the clinical studies with
the monoclonal antibody Daratumumab in relapsed Multiple Myeloma and anti CD19 CAR T cells in relapsed Lymphoma. Her translational research focuses on the immunotherapy for multiple myeloma, bone remodeling after successful anti myeloma treatment and the possibilities of personalized cancer treatment in this bone marrow cancer. She was a member of the organizing committee of the Waldenström workshop in Amsterdam in 2016.

Research Output (92)

Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP

Hayden Patrick J, Iacobelli Simona, Pérez-Simón José Antonio, van Biezen Anja, Minnema Monique, Niittyvuopio Riitta, Schönland Stefan, Meijer Ellen, Blaise Didier, Milpied Noel, Márquez-Malaver Francisco J, Veelken Joan Hendrik, Maertens Johan, Michallet Mauricette, Cammenga Jörg, N'Guyen Stephanie, Niederwieser Dietger, Hunault-Berger Mathilde, Henri Bourhis Jean, Passweg Jakob, Bermudez Arancha, Chalandon Yves, Yakoub-Agha Ibrahim, Garderet Laurent, Kröger Nicolaus mrt 2020, In: European Journal of Haematology. 104 , p. 181-189 9 p.

Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)

Topp Max S., van Meerten Tom, Houot Roch, Minnema Monique, Milpied Noel, Lugtenburg Pieternella J., Thieblemont Catherine, Wermke Martin, Song Kevin, Avivi Irit, Kuruvilla John, Duehrsen Ulrich, Chu Rachel, Zheng Lianqing, Plaks Vicki, Kerber Anne, Kersten Marie Jose mrt 2020, In: Biology of Blood and Marrow Transplantation. 26 , p. S101-S101

Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting

Slomp Anne, Moesbergen Laura M, Gong Jia-Nan, Cuenca Marta, von dem Borne Peter A, Sonneveld Pieter, Huang David C S, Minnema Monique C, Peperzak Victor 23 dec 2019, In: Blood Advances. 3 , p. 4202-4214 13 p.

Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia:a single-arm, multicentre, phase 2 study

Owen Roger G, McCarthy Helen, Rule Simon, D'Sa Shirley, Thomas Sheeba K, Tournilhac Olivier, Forconi Francesco, Kersten Marie José, Zinzani Pier Luigi, Iyengar Sunil, Kothari Jaimal, Minnema Monique C, Kastritis Efstathios, Aurran-Schleinitz Thérèse, Cheson Bruce D, Walter Harriet, Greenwald Daniel, Chen Dih-Yih, Frigault Melanie M, Hamdy Ahmed, Izumi Raquel, Patel Priti, Wei Helen, Lee Sun Ku, Mittag Diana, Furman Richard R 19 dec 2019, In: Lancet haematology. 7 , p. e112-e121 10 p.

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial

Minnema Monique C., Nasserinejad Kazem, Hazenberg Bouke, Hegenbart Ute, Vlummens Philip, Ypma Paula F., Kroeger Nicolaus, Wu Ka Lung, Kersten Marie Jose, Schaafsma M. Ron, Croockewit Sandra, de Waal Esther, Zweegman Sonja, Tick Lidwien, Broijl Annemieke, Koene Harry, Bos Gerard, Sonneveld Pieter, Schoenland Stefan nov 2019, In: Haematologica. 104 , p. 2274-2282 9 p.

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial

Wester Ruth, van der Holt Bronno, Asselbergs Emelie, Zweegman Sonja, Kersten Marie Jose, Vellenga Edo, Kooy Marinus van Marwijk, de Weerdt Okke, Minnema Monique, Lonergan Sarah, Palumbo Antonio, Lokhorst Henk, Broijl Annemiek, Sonneveld Pieter nov 2019, In: Haematologica. 104 , p. 2265-2273 9 p.

Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA

Sonneveld Pieter, Attal Michel, Perrot Aurore, Hulin Cyrille, Caillot Denis, Facon Thierry, Leleu Xavier, Belhadj-Merzoug Karim, Karlin Lionel, Benboubker Lofti, Levin Mark-David, Minnema Monique, Westerman Matthijs, Delforge Michel, Zweegman Sonja, Pei Lixia, de Boer Carla, Vanquickelberghe Veronique, Kampfenkel Tobias, Moreau Philippe okt 2019, In: Clinical Lymphoma, Myeloma and Leukemia. 19 , p. E2-E3

A Phase 1b/2a Study of the CELMoD Iberdomide (CC-220) in Combination With Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Lonial Sagar, Van de Donk Niels, Popat Rakesh, Zonder Jeffrey A., Minnema Monique, Larsen Jeremy T., Tuong Vi Nguyen , Chen Min S., Bensmaine Amine, Peluso Teresa, Sonneveld Pieter okt 2019, In: Clinical Lymphoma, Myeloma and Leukemia. 19 , p. E52-E53

Eight versus four induction cycles of Carfilzomib, Thalidomide and Low-dose Dexamethasone: the Carthadex trial

Wester Ruth, Zweegman Sonja, Van der Holt Bronno, Jose Kersten Marie, Vellenga Edo, van Marwijk-Kooy Marinus, Asselbergs Emelie, de Weerdt Okke, Minnema Monique, Lonergan Sarah, Palumbo Antonio, Broijl Annemiek, Sonneveld Pieter okt 2019, In: Clinical Lymphoma, Myeloma and Leukemia. 19 , p. E220-E221

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study

Plesner Torben, Arkenau Hendrik-Tobias, Gay Francesca, Minnema Monique C., Boccadoro Mario, Moreau Philippe, Cavenagh Jamie, Perrot Aurore, Laubach Jacob P., Krejcik Jakub, Ahmadi Tahamtan, de Boer Carla, Chen Diana, Chiu Christopher, Schecter Jordan M., Richardson Paul G. aug 2019, In: British Journal of Haematology. 186 , p. E35-E39

All Research Output (92)
To top